Page last updated: 2024-10-15

iodinin

Description

iodinin: antibiotic pigment from Chromobacterium iodinum; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135441735
CHEMBL ID1987496
SCHEMBL ID3583519
MeSH IDM0051715

Synonyms (18)

Synonym
NCI60_003788
68-81-5
iodinin
1,10-dioxide
nsc-402910
nsc402910
1, 5,10-dioxide
iodinine
5,6-dihydroxy-10-oxidophenazin-10-ium-1-one
5,10-dioxidophenazine-5,10-diium-1,6-diol
1,6-phenazinediol, 5,10-dioxide
g1239096eo ,
1,6-dihydroxyphenazine-5,10-dioxide
1,6-phenazinediol 5,10-dioxide
iodinin [mi]
SCHEMBL3583519
CHEMBL1987496
Q27278504

Bioavailability

ExcerptReference
" It was used here to enhance the bioavailability of the biologically important compound iodinin, which is near insoluble in aqueous solutions."( Enhancement of iodinin solubility by encapsulation into cyclodextrin nanoparticles.
Døskeland, SO; Herfindal, L; Le Borgne, M; Perret, F; Prandina, A; Radix, S; Rongved, P, 2018
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1726722Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by WST-1 assay2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1726725Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by WST-1 assay2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1364440Antiproliferative activity against human MOLM13 cells assessed as change in nuclear morphology up to 10 uM treated for 24 hrs post incubation under 2% O2 condition for 2 days by Hoechst 33342 staining-based UV-microscopic analysis2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID1364438Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by WST-1 assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID1726731Effective permeability of the compound in PBS at 50 uM incubated for 5 hrs by PAMPA2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1424145Antibacterial activity against Enterococcus faecium CCUG 37832 incubated for 18 hrs by WST1 assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
AID1726721Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by WST-1 assay2021RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells.
AID1364436Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by WST-1 assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives.
AID1424146Antibacterial activity against Enterococcus faecium CTC 492 incubated for 18 hrs by WST1 assay2017Journal of natural products, 04-28, Volume: 80, Issue:4
Antibacterial Compounds from Marine Bacteria, 2010-2015.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (30.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]